BIOMEA FUSION INC. -

Biomea Fusion Announces Dosing of First Patient with Type 2 Diabetes and Completion of Phase I Healthy Volunteer Portion of Phase I/II (COVALENT-111) Study of BMF-219

31 Oct 2022 07:00:01 By Nasdaq GlobeNewswire

Biomea Fusion Announces First Patient Dosed with Chronic Lymphocytic Leukemia (CLL) in COVALENT-101 Trial

27 Oct 2022 07:00:01 By Nasdaq GlobeNewswire

BMF-219 Enters the Clinic for KRAS Solid Tumors

14 Oct 2022 08:00:00 By Nasdaq GlobeNewswire

Biomea Fusion Presents New Translational Data at the European Association for the Study of Diabetes (EASD) 2022 in Animal Models and Ex-vivo Human Donor Islets Further Supporting BMF-219’s Potential as an Oral, Long-Acting Treatment for Type 2 Diabetes

22 Sep 2022 08:30:00 By Nasdaq GlobeNewswire

Biomea Fusion Presents New Preclinical Data at the European Association for the Study of Diabetes (EASD) Annual Meeting Describing BMF-219’s Potential as a Novel, Oral, Long-Acting Treatment for Type 2 Diabetes

20 Sep 2022 06:30:00 By Nasdaq GlobeNewswire

Biomea Fusion Presents Additional Preclinical Data Demonstrating Anti-Tumor Activity and Mechanistic Evidence for BMF-219 in Diffuse Large B-Cell Lymphoma and Multiple Myeloma Models at International Myeloma Society Annual Meeting

26 Aug 2022 07:30:00 By Nasdaq GlobeNewswire

Biomea Fusion Reports Second Quarter 2022 Financial Results and Business Highlights

01 Aug 2022 15:05:01 By Nasdaq GlobeNewswire

Biomea Fusion Selected for Two Oral Presentations at the European Association for the Study of Diabetes Annual Meeting Describing BMF-219’s Potential as a Novel, Oral, Long-Acting, Acute Treatment for Type 2 Diabetes

01 Jul 2022 07:30:00 By Nasdaq GlobeNewswire

Biomea Fusion Announces First Patient Dosed in Multiple Myeloma Cohort of COVALENT-101 Trial

22 Jun 2022 07:30:00 By Nasdaq GlobeNewswire

Biomea Fusion Presents Novel Preclinical Data at ADA 2022 Suggesting BMF-219’s Potential as an Oral, Long-Acting Treatment for Type 2 Diabetes

04 Jun 2022 10:00:00 By Nasdaq GlobeNewswire

Biomea Fusion to Participate in Jefferies Healthcare Conference

02 Jun 2022 17:00:00 By Nasdaq GlobeNewswire

Biomea Fusion to Present New Preclinical Data on BMF-219 in Two Diabetic Animal Models at ADA 2022

01 Jun 2022 07:30:00 By Nasdaq GlobeNewswire

Biomea Fusion to Present New Preclinical Data Showing BMF-219’s Strong Activity in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Tumor Models at ASCO 2022

26 May 2022 17:30:00 By Nasdaq GlobeNewswire

Biomea Fusion to Attend H.C. Wainwright Global Investment Conference

20 May 2022 12:30:00 By Nasdaq GlobeNewswire

Biomea Fusion Announces IND Candidate Selection: BMF-500, a Potential Best-in-Class Oral Covalent Inhibitor of FLT3

19 May 2022 07:00:00 By Nasdaq GlobeNewswire

Biomea Fusion Reports First Quarter 2022 Financial Results and Business Highlights

16 May 2022 06:30:00 By Nasdaq GlobeNewswire

Biomea Fusion to Participate in Bank of America Securities 2022 Healthcare Conference

09 May 2022 15:30:00 By Nasdaq GlobeNewswire

Biomea Fusion Announces Acceptance of Multiple Abstracts at the 2022 ASCO Annual Meeting

27 Apr 2022 15:00:00 By Nasdaq GlobeNewswire

Biomea Fusion Reports Preclinical Data on BMF-219 and Trial in Progress Presentations at AACR 2022 Annual Meeting

08 Apr 2022 12:00:00 By Nasdaq GlobeNewswire

Biomea Fusion Announces Acceptance of Late Breaking Presentation of Lead Menin Inhibitor BMF-219 in Diabetes at ADA 82nd Scientific Sessions 2022

06 Apr 2022 16:00:00 By Nasdaq GlobeNewswire